US Institute of Medicine panel says Congress should have more power to order post-market studies
This article was originally published in Clinica
US Congress should give the FDA expanded authority to order post-market studies when issuing a pre-market notification or a 510(k), says a new report issued by a panel of experts convened by the Institute of Medicine (IoM).
You may also be interested in...
Can shaving ever be “friction free”? Not according to Procter & Gamble, which challenged in a complaint to the UK Advertising Standards Authority a claim made by a British cosmetics firm FFS that it provided a “friction free” shaving experience for women via its subscription razor service.
Work has started on UK-only regulations for the medtech and medicines sectors, to ensure that the regulatory framework not only functions but can also react swiftly to needs after the UK leaves the EU. This article is part two of two.